CA 19-9 and survival in advanced and unresectable pancreatic adenocarcinoma and cholangiocarcinoma

被引：18

作者：

Ali C.W. ^{[1
,3
]}

Kaye T.F. ^{[1
]}

Adamson D.J.A. ^{[1
]}

Tait I.S. ^{[2
]}

Polignano F.M. ^{[2
]}

Highley M.S. ^{[1
]}

机构：

[1] Department of Cancer Medicine, Ninewells Hospital

[2] Department of Surgery, Ninewells Hospital

[3] Flat 20 Caird House, Dundee DD36TU

来源：

Journal of Gastrointestinal Cancer | 2007年 / 38卷 / 2-4期

关键词：

CA; 19-9; antigen; Cholangiocarcinoma; Pancreatic neoplasms;

D O I：

10.1007/s12029-008-9019-x

中图分类号：

学科分类号：

摘要：

Background: The CA 19-9 tumour marker is increasingly used to monitor response to therapy in patients with pancreatic adenocarcinoma. Serum CA 19-9 levels have also been shown to correlate with survival. However, their role in cholangiocarcinoma is less clear. Aim of study: To assess the utility of CA 19-9 levels in the management of patients with advanced pancreatic adenocarcinoma or cholangiocarcinoma in routine clinical practice is the aim of the study. Methods: A retrospective analysis of CA 19-9 values and survival was performed in 26 patients with pancreatic adenocarcinoma receiving gemcitabine and in 18 patients with cholangiocarcinoma. Results: Patients with advanced pancreatic adenocarcinoma receiving gemcitabine who experienced a decrease of 20% in CA 19-9 concentration had a median survival of 13.9+ months (range 4.2-23.5) compared to 7.6+ months (range 4.0-14.7) in those without such a change (p∈=∈0.0109). In patients with advanced cholangiocarcinoma, the median survival was longest in those with a baseline CA 19-9 level of less than 1,000 U/ml; 11.8 months (range 1.0-41.4) vs 6.2 months (range 3.1-9.4; p∈=∈0.0075). Conclusions: The CA 19-9 concentration has a valuable role in predicting outcome in patients with pancreatic adenocarcinoma and cholangiocarcinoma. It is helpful in guiding therapy and should be used accordingly in oncology practice. © 2008 Humana Press Inc.

引用

页码：108 / 114

页数：6

共 21 条

[1]

Koprowski H., Steplewski Z., Mitchell K., Herlyn M., Herlyn D., Fuhrer P., Colorectal carcinoma antigens detected by hybridoma antibodies, Somat Cell Genet, 5, pp. 957-971, (1979)

[2]

Duffy M.J., CA 19-9 as a marker for gastrointestinal cancers: A review, Ann Clin Biochem, 35, pp. 364-370, (1998)

[3]

Glenn J., Steinberg W.M., Kurtzman S.H., Steinberg S.M., Sindelar W.F., Evaluation of the utility of a radioimmunoassay for serum CA19-9 levels in patients before and after treatment of carcinoma of the pancreas, J Clin Oncol, 6, pp. 462-468, (1988)

[4]

Yasue M., Sakamoto J., Teramukai S., Morimoto T., Yasui K., Kuno N., Kurimoto K., Ohashi Y., Prognostic values of preoperative and postoperative CEA and CA19.9 levels in pancreatic cancer, Pancreas, 9, pp. 735-740, (1994)

[5]

Steinberg W., The clinical utility of the CA 19-9 tumor-associated antigen, Am J Gastroenterol, 85, pp. 350-355, (1990)

[6]

Micke O., Bruns F., Kurowski R., Horst E., Devries A.F., Hausler J.W., Willich N., Schafer U., Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy, Int J Radiat Oncol Biol Phys, 57, pp. 90-97, (2003)

[7]

Halm U., Schumann T., Schiefke I., Witzigmann H., Mossner J., Keim V., Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer, Br J Cancer, 82, pp. 1013-1016, (2000)

[8]

Saad E.D., MacHado M.C., Wajsbrot D., Abramoff R., Hoff P.M., Tabacof J., Katz A., Simon S.D., Gansl R.C., Pretreatment CA19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine, Int J Gastrointest Cancer, 32, pp. 35-41, (2002)

[9]

Ziske C., Schlie C., Gorschluter M., Glasmacher A., Mey U., Strehl J., Sauerbruch T., Schmidt-Wolf I.G.H., Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine, Br J Cancer, 89, pp. 1413-1417, (2003)

[10]

Ko A.H., Hwang J., Venook A.P., Abbruzzese J.L., Bergsland E.K., Tempero M.A., Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose gemcitabine for advanced pancreatic cancer, Br J Cancer, 93, pp. 195-199, (2005)

← 1 2 3 →